申请人:BTG INT LTD
公开号:WO2009103950A1
公开(公告)日:2009-08-27
Metal chelating compounds of formula (I) are provided: or tautomers thereof or a pharmaceutically acceptable salt of either characterised in that R1 is selected from the group H and C1-6 alkyl R2, R4 and R5 are independently selected from the group H, C1-6 alkyl, Cl, F, -CHF2, CF3, -C(O)CF3, -CH(OH)CF3 and R6 R3 is selected from the group H, C1-6 alkyl and C1-6 acyl R6 is a group -C(O)-N(R7)(R8) R7 is selected from H and C1-6 alkyl and R8 is selected from H, C1-6 alkyl and a group -CH(R9CO)-N(R10XR11 ). R9 and R10 are independently selected from H, C1-6 alkyl and C1-10 aralkyl and R11 is selected from H and C1-6 alkyl, or R10 and R11 together with the nitrogen to which they are bonded form a 3-8 membered heterocyclic ring wherein at least one of R2, R4 and R5 is F. The compounds of the invention have reduced susceptibility to glucuronidation and microsomal oxidation as compared to current clinical compounds of the same class but in preferred forms have lower molecular weight and have blood brain barrier permeability.
提供了化学式(I)的金属螯合化合物:或其互变异构体或两者中的任何一种的药用盐,其中R1选自H和C1-6烷基,R2、R4和R5分别选自H、C1-6烷基、Cl、F、-CHF2、CF3、-C(O)CF3、-CH(OH)CF3和R6,R3选自H、C1-6烷基和C1-6酰基,R6是一个基团-C(O)-N(R7)(R8),R7选自H和C1-6烷基,R8选自H、C1-6烷基和一个基团-CH(R9CO)-N(R10XR11)。R9和R10分别选自H、C1-6烷基和C1-10芳基烷基,R11选自H和C1-6烷基,或R10和R11与它们结合的氮共同形成一个3-8成员杂环,其中R2、R4和R5中至少有一个是F。该发明的化合物相比于同类当前临床化合物具有较低的葡萄糖醛酸化和微粒体氧化敏感性,但在优选形式中具有较低的分子量和血脑屏障透过性。